Updates on hormone receptor-positive HER2-negative breast cancer
Dr Aurelio Castrellon speaks to ecancer at the 2019 ASCO Direct Highlights Symposium in Miami about the important developments in the treatment of hormone receptor-positive HER2-negative breast cancer.
He describes two main studies in patients with stage IV breast cancer, specifically in premenopausal patients and includes the MONALEESA-7 trial and the KCSG-BR 15-10 study.
Dr Castrellon also details two further studies which assessed the use of pembrolizumab combined with eribulin in this disease setting and the combination of fulvestrant with capivasertib (an AKT-inhibitor).
He concludes by mentioning the mutation FAT1, which may confer intrinsic resistance to CDK4/6 inhibition in these patients.
Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php
Видео Updates on hormone receptor-positive HER2-negative breast cancer канала ecancer
He describes two main studies in patients with stage IV breast cancer, specifically in premenopausal patients and includes the MONALEESA-7 trial and the KCSG-BR 15-10 study.
Dr Castrellon also details two further studies which assessed the use of pembrolizumab combined with eribulin in this disease setting and the combination of fulvestrant with capivasertib (an AKT-inhibitor).
He concludes by mentioning the mutation FAT1, which may confer intrinsic resistance to CDK4/6 inhibition in these patients.
Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php
Видео Updates on hormone receptor-positive HER2-negative breast cancer канала ecancer
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
![Treatment Options for ER/PR Positive Breast Cancers](https://i.ytimg.com/vi/4OxxQZUcVeg/default.jpg)
![Adjuvant therapy for early stage ER-positive, HER2-negative invasive breast cancer](https://i.ytimg.com/vi/s1gsCFJVrWk/default.jpg)
![Estrogen Receptors & HER2/neu Receptors in Breast Cancer (a TUTORIAL from Oster Oncology)](https://i.ytimg.com/vi/BojDeabPQTs/default.jpg)
![Ask the expert: Early-stage hormone receptor-positive, HER2-positive & triple-positive breast cancer](https://i.ytimg.com/vi/sYseiGzgf6Q/default.jpg)
![New Advances and Opportunities for Improvement in HR+/HER2- Early Breast Cancer](https://i.ytimg.com/vi/9nY1XgjiBSI/default.jpg)
![HER2-Targeted Therapy in Early Stage HER2+ Breast Cancer](https://i.ytimg.com/vi/owxx51yuXBo/default.jpg)
![What Is the Best Diet and Lifestyle During Breast Cancer?](https://i.ytimg.com/vi/OImlGPlywQs/default.jpg)
![CDK4/6 inhibitor abemaciclib plus fulvestrant improves overall survival in HR-positive/HER2-nega...](https://i.ytimg.com/vi/1D_hL2ob_WE/default.jpg)
![Understanding Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer (MBC)](https://i.ytimg.com/vi/HhmH2PObyAU/default.jpg)
![Optimizing Treatment Options for HER2+/ ER+ Breast Cancer using Models of Endocrine Resistance](https://i.ytimg.com/vi/CKpS7n9vvkM/default.jpg)
![Medical Update: Triple-Negative Metastatic Breast Cancer](https://i.ytimg.com/vi/RjS_-FKKx-o/default.jpg)
![Breast Cancer Immunotherapy with Dr. Sylvia Adams and Victor Ty, BSN, RN](https://i.ytimg.com/vi/Zjm1spIkYBo/default.jpg)
![Breast Cancer Receptors: ER/PR | MADE EASY](https://i.ytimg.com/vi/tx84NjDHnhU/default.jpg)
![Diet, cancer, and patient control: how fasting, IGF-I, and blood sugar impact care with Dr. Dawn...](https://i.ytimg.com/vi/FBIslLSL5n0/default.jpg)
![Ultrasound Imaging of the Breast – Lesion Characterization](https://i.ytimg.com/vi/jiY08Frt4JM/default.jpg)
![Biomarker guidance allows patients 55 or older with low-grade luminal A-type breast cancer to av...](https://i.ytimg.com/vi/_smGRJk4j-4/default.jpg)
![Tamoxifen and Aromatase Inhibitors](https://i.ytimg.com/vi/gHKTI1-Yol8/default.jpg)
![EHA update: Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDMM](https://i.ytimg.com/vi/iMsjlSG6yEU/default.jpg)
![5. What is ER, PR, HER2?](https://i.ytimg.com/vi/V16Wgs1NBg4/default.jpg)
![Quizartinib improves overall survival in adult patients with FLT3-ITD+ acute myeloid leukaemia](https://i.ytimg.com/vi/8URzoXSrNFA/default.jpg)